| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Factors Affecting Treatment and Recurrence of Clostridium difficile Infections |
|
言語 |
en |
| 作成者 |
Matsumoto, Kazuaki
Kanazawa, Naoko
Shigemi, Akari
Ikawa, Kazuro
Morikawa, Norifumi
Koriyama, Toyoyasu
Orita, Michiyo
Kawamura, Hideki
Tokuda, Koichi
Nishi, Junichiro
Takeda, Yasuo
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
Copyright (c) 2014 The Pharmaceutical Society of Japan |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Clostridium difficile |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
antiinfective agent |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
gastric acid-suppressive agent |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
anticancer agent |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
steroid |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
recurrence |
| 主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
| 内容記述 |
|
|
内容記述 |
The antimicrobial agents vancomycin and metronidazole have been used to treat Clostridium difficile infections (CDIs). However, it remains unclear why patients are at risk of treatment failure and recurrence. Therefore, this study retrospectively examined 98 patients with CDIs who were diagnosed based on the detection of toxin-positive C. difficile to determine the risk factors affecting drug treatment responses and the recurrence of CDI. No significant difference was observed in the cure rate or dosage between the vancomycin and metronidazole groups. The 90-d mortality rate and total number of drugs associated with CDIs, including antiinfective agents used within 2 months before the detection of toxin-positive C. difficile, were significantly lower in the treatment success group than in the failure group. The total number of antiinfective agents and gastric acid-suppressive agents used during CDI therapy was also significantly lower in the success group than in the failure group. The period from the completion of CDI therapy to restarting the administration of anticancer agents and steroids was significantly longer in patients without than in patients with recurrence. These results indicate that the total number of drugs associated with CDIs should be minimized to reduce the risk of CDIs, that not only antibiotics but also gastric acid-suppressive agents should be discontinued during CDI therapy to increase therapeutic efficacy, and that the use of anticancer agents and steroids should be delayed as long as possible after patients are cured by CDI therapy to prevent recurrence. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
The Pharmaceutical Society of Japan |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1248/bpb.b14-00492 |
| 関連情報 |
|
|
|
識別子タイプ |
NAID |
|
|
関連識別子 |
130004703902 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1248/bpb.b14-00492 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0918-6158 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1347-5215 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10885497 |
| 開始ページ |
|
|
開始ページ |
1811 |
| 書誌情報 |
Biological and Pharmaceutical Bulletin
Biological and Pharmaceutical Bulletin
巻 37,
号 11,
p. 1811-1815,
発行日 2014-11-01
|
| 旧ID |
46717 |
BiolPharmBull_37_1811.pdf (381.2 KB)
